Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

globenewswire

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC – NEWSnet – News… as it used to be

More Press Releases

August 10, 2026

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

August 10, 2026

HBT Financial, Inc. and Tri-County Financial Group, Inc. Jointly Announce Strategic Transaction

August 10, 2026

NRSInsights’ July 2026 Retail Same-Store Sales Report

August 10, 2026

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

HBT Financial, Inc. and Tri-County Financial Group, Inc. Jointly Announce Strategic Transaction

NRSInsights’ July 2026 Retail Same-Store Sales Report

SKYX Announces Corporate Update Call